New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT04158336
Summary
This early-stage study tested a new oral drug called ZN-c3 in adults with advanced solid tumors that had stopped responding to standard treatments. Researchers aimed to find the safest dose and see if the drug shows any signs of fighting cancer. The trial also checked whether taking the drug with food affects how the body processes it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 0100
San Antonio, Texas, 78229, United States
-
Site 0101
Detroit, Michigan, 48201, United States
-
Site 0102
Tucson, Arizona, 85719, United States
-
Site 0103
Houston, Texas, 77030, United States
-
Site 0167
Newport Beach, California, 92663, United States
-
Site 0171
Chicago, Illinois, 60637, United States
-
Site 0173
New York, New York, 10029, United States
-
Site 0179
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.